EMPAGLIFLOZIN AND DAPAGLIFLOZIN IN IMPROVING EJECTION FRACTION: A PROSPECTIVE OBSERVATIONAL COMPARISON OF CLINICAL OUTCOMES AND PATIENT REPORTED QUALITY OF LIFE
Background: SGLT2 inhibitors have transformed heart failure treatment, especially empagliflozin and dapagliflozin. Although both have proven cardiovascular benefits in clinical trials, there is little data comparing them in real-world settings. This study aims to address that by comparing their effects on heart functio...